- Home
- EVN vs CLLS Comparison
EVN vs CLLS Comparison
Compare EVN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVN | CLLS |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.2M | 374.2M |
| IPO Year | 1998 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EVN | CLLS |
|---|---|---|
| Price | $10.90 | $3.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 56.5K | 30.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $40.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.59 | $1.10 |
| 52 Week High | $11.23 | $5.48 |
Technical Indicators
Market Signals| Indicator | EVN | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 42.55 |
| Support Level | $10.81 | $3.41 |
| Resistance Level | $11.17 | $3.77 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 32.00 | 15.58 |
Price Performance
Historical ComparisonAbout EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.